Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
Budesonide and mesalazine in active Crohn's disease: A comparison of the effects on quality of life
American Journal of Gastroenterology, Volume 97, No. 3, Year 2002
Notification
URL copied to clipboard!
Description
ObjectiveS: Controlled ileal release budesonide and slow release mesalazine are both used to treat mild to moderate active Crohn's disease, although data show that budesonide is more effective in inducing remission. When comparing different treatment options, the effects of agents on healthrelated quality of life must be considered as well as efficacy. In this study, we sought to compare the effects of budesonide and mesalazine on the health-related quality of life of patients with active Crohn's disease. METHODS: The study included 182 patients with Crohn's Disease Activity Index scores between 200 and 400. Patients were randomized in a double blind, double dummy, multicenter study to receive 9 mg of budesonide, once daily (n = 93), or 2 g of mesalazine, b.i.d. (n = 89), for 16 wk. Quality of life was assessed at baseline and after 2, 4, 8, 12, and 16 wk of treatment using the Psychological General Well-Being index. In addition, a physician's global evaluation was used to assess how symptoms affected patients' normal activities. RESULTS: Patients treated with budesonide experienced significantly greater improvement in Psychological General Well-Being scores than the group treated with mesalazine after 2, 8, 12, and 16 wk. All components of this index showed greater improvements in the budesonide-treated group than in the mesalazine group at 12 and 16 wk. The physician's global evaluation showed significantly greater improvements in the budesonide group than in the mesalazine group at all visits. CONCLUSION: Budesonide (9 mg once daily) improves health-related quality of life to a greater extent than mesalazine (2 g b.i.d.) in patients with mild to moderate active Crohn's disease. © 2002 by Am. Coll. of Gastroenterology.
Authors & Co-Authors
Thomsen, Ole
Denmark, Hellerup
Gentofte Hospital
Cortot, Antoine
France, Lille
Chu Lille
Jewell, Derek P.J.
United Kingdom, Oxford
John Radcliffe Hospital
Wright, John P.
South Africa, Cape Town
Kingsbury Hospital
Winter, Trevor A.
South Africa, Observatory
Groote Schuur Hospital
Veloso, Fernando T.
Portugal, Porto
Sao Joao Hospital
Vatn, Morten Harald
Norway, Oslo
Rikshospitalet-radiumhospitalet hf
Persson, Tore
Sweden, Sodertalje
Astrazeneca Sweden
Pettersson, Eva
Sweden, Sodertalje
Astrazeneca Sweden
Statistics
Citations: 14
Authors: 9
Affiliations: 8
Identifiers
Doi:
10.1111/j.1572-0241.2002.05544.x
Research Areas
Disability